Skip to main content

Table 2 Regression results predicting HRQoL in the US (a) and EU5 (b)

From: The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe

a)

 

US

EQ-5D utility score

N = 236

EQ-5D VAS

N = 235

SIBDQ

N = 232

b

95% CI

P

b

95% CI

P

b

95% CI

P

Intercept

0.830

0.703, 0.958

< 0.001

74.730

60.705, 88.755

< 0.001

3.851

2.71, 4.993

< 0.001

 Age

0.000

−0.002, 0.001

0.782

− 0.113

− 0.281, 0.056

0.189

0.006

− 0.008, 0.019

0.426

 Female

−0.009

− 0.046, 0.028

0.641

−2.278

−6.384, 1.828

0.277

−0.071

− 0.408, 0.265

0.678

 BMI

−0.001

−0.005, 0.003

0.664

−0.160

− 0.594, 0.273

0.469

0.009

−0.027, 0.044

0.626

Smoking status

 Current smokera

 Former smoker

0.096

0.025, 0.167

0.008

7.259

−0.552, 15.07

0.069

0.290

−0.345, 0.925

0.370

 Never smoker

0.080

0.011, 0.148

0.023

8.480

0.929, 16.032

0.028

0.259

−0.354, 0.873

0.408

CCI

−0.045

− 0.082, − 0.007

0.020

−5.415

−9.399, −1.431

0.008

− 0.293

− 0.618, 0.032

0.077

Years diagnosed

0.000

−0.003, 0.004

0.759

−0.031

− 0.368, 0.306

0.856

0.023

−0.004, 0.051

0.096

Disease activity

 Active diseasea

 Remission

0.053

0.014, 0.093

0.008

11.554

7.191, 15.917

< 0.001

0.856

0.501, 1.211

< 0.001

 Deep remission

0.065

0.004, 0.126

0.036

17.803

11.095, 24.511

< 0.001

1.299

0.746, 1.851

< 0.001

b)

 

EU5

EQ-5D utility score

N = 790

EQ-5D VAS

N = 786

SIBDQ

N = 758

b

95% CI

P

b

95% CI

P

b

95% CI

P

Intercept

0.853

0.78, 0.926

< 0.001

69.701

61.817, 77.586

< 0.001

4.532

4.014, 5.05

< 0.001

Country

 Francea

 Germany

0.055

0.029, 0.081

< 0.001

1.500

−1.3, 4.299

0.294

0.067

−0.118, 0.252

0.477

 Italy

0.069

0.016, 0.122

0.011

3.745

−1.932, 9.422

0.196

0.298

−0.084, 0.680

0.126

 Spain

0.042

0.011, 0.073

0.009

0.230

−3.112, 3.572

0.893

−0.062

−0.281, 0.157

0.578

 UK

0.011

−0.036, 0.058

0.636

−0.617

−5.606, 4.372

0.808

−0.337

−0.659, − 0.016

0.040

Age

−0.001

−0.002, 0.000

0.050

−0.066

− 0.164, 0.032

0.185

− 0.007

−0.013, 0.000

0.051

Female

−0.027

−0.049, − 0.006

0.014

−1.582

−3.934, 0.770

0.187

− 0.215

−0.37, − 0.06

0.007

BMI

−0.002

−0.004, 0.001

0.166

−0.075

− 0.352, 0.201

0.593

0.001

−0.017, 0.019

0.914

Smoking status

 Current smokera

 Former smoker

− 0.019

− 0.051, 0.013

0.247

−3.896

−7.341, − 0.450

0.027

− 0.175

− 0.405, 0.054

0.135

 Never smoker

0.001

−0.029, 0.031

0.942

−0.809

−4.005, 2.387

0.620

0.072

−0.142, 0.286

0.509

CCI

−0.004

−0.023, 0.015

0.673

−2.451

−4.572, − 0.331

0.023

− 0.143

−0.286, 0.001

0.051

Years diagnosed

−0.002

− 0.004, 0.000

0.122

− 0.211

− 0.424, 0.001

0.051

0.002

− 0.012, 0.016

0.784

Disease activity

 Active diseasea

 Remission

0.131

0.108, 0.154

< 0.001

17.034

14.529, 19.538

< 0.001

1.386

1.221, 1.552

< 0.001

 Deep remission

0.127

0.094, 0.161

< 0.001

18.191

14.596, 21.785

< 0.001

1.558

1.322, 1.795

< 0.001

  1. Abbreviations: b regression estimate, BMI body mass index, CCI Charlson Comorbidity Index, CI confidence interval, EQ-5D EuroQoL-5 Dimensions, EU5 European Union 5 (France, Germany, Italy, Spain, the UK), HRQoL health-related quality of life, SIBDQ Short Quality of Life in Inflammatory Bowel Disease Questionnaire, UK United Kingdom, US United States, VAS visual analog scale
  2. aIndicates reference category